Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 8/20 | 0.48 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 5/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.42 |
| ▸ | CYP2B6 | P20813 | 3/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.42 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1356290 | 0.86 | GRM5 (0.50) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL1358475 | 0.82 | MTOR (0.48) | CYP1A2CYP2A6CYP2B6CYP2C19CYP2E1 | |
| SCHEMBL12135359 | 0.81 | ADORA1 (0.54) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL12135288 | 0.80 | ADORA2A (0.47) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL12135307 | 0.80 | ADORA2A (0.52) | GRM5CYP2D6CYP1A2 | |
| SCHEMBL12135452 | 0.79 | GRM5 (0.43) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL1357751 | 0.79 | MTOR (0.50) | — | |
| SCHEMBL503533 | 0.78 | GRM5 (0.47) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL12135310 | 0.78 | ADORA2A (0.42) | GRM5CYP2D6CYP1A2CYP2A6CYP2C9 | |
| SCHEMBL12135765 | 0.77 | PIK3CA (0.44) | GRM5CYP2D6CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323992-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| EP-2323992-B1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INT (DE) | 2016-07-20 | — | — | EP | disclosed |
| US-8916548-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916548-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-8916548-B2 | 5-alkynyl-pyrimidines | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| US-20110281838-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| US-20110281838-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-17 | — | — | US | disclosed |
| EP-2323992-A1 | 5-ALKYNYL-PYRIMIDINES | Boehringer Ingelheim International GmbH (DE) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010012740-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
| WO-2010012740-A1 | 5-ALKYNYL-PYRIMIDINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110281838-A1 | 5-ALKYNYL-PYRIMIDINES | MKI67, CCNA1, CCNT1 | GRM5 2658/4885CYP2D6 292/4885CYP1A2 335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.